Key result
Hypertensive patients with moderate chronic renal failure had higher baseline plasma DOPA sulfate concentrations compared to hypertensives without renal failure.
Why the study?
The role of dopamine deficiency and its metabolites in hypertensive patients with and without moderate chronic renal failure was unclear.
Does oral DOPA administration reveal differences in dopamine generation and sulfate clearance in hypertensive patients with and without chronic renal failure compared to controls?
Cross-Sectional (n=27)
No
Does oral DOPA administration reveal differences in dopamine generation and sulfate clearance in hypertensive patients with and without chronic renal failure compared to controls?
Defective dopamine generation from DOPA is common in hypertension, and moderate chronic renal failure further alters DOPA and dopamine sulfate metabolism, potentially perpetuating renal failure.
Answers are grounded in this paper and cite their sources.
May implicate dopamine pathways in hypertension; hypothesis-generating for CRF-specific mechanisms before any clinical application.
Baseline dihydroxyphenylalanine (DOPA) and dopamine (DA), their respective sulfates as well as oral DOPA administration-induced changes were compared in age- and blood pressure-matched hypertensive patients without and with moderate chronic renal failure (CRF) and control subjects. The only common feature of both hypertensive groups was a defective DA generation from DOPA. Hypertensive patients with moderate CRF were distinct from those without, having increased basal concentrations of plasma DOPA and DA sulfates. After oral DOPA administration, plasma and urinary DOPA sulfate rose while renal DA sulfate clearance was decreased. Possible enzymatic defects contributing to CRF-induced increases of DOPA and DA sulfates and their potential role in perpetuating renal failure via glomerular hypertension are discussed.
No takes yet. Share an insight, caveat, or question.
Kuchel et al. (1995) conducted a cross-sectional in Hypertension with and without chronic renal failure (n=27). Oral DOPA vs. Hypertensives without CRF and normotensive controls was evaluated on Baseline plasma DOPA sulfate concentration (pmol/ml) (p=<0.05). Hypertensive patients with moderate chronic renal failure had higher baseline plasma DOPA sulfate concentrations compared to hypertensives without renal failure.
Synapse has enriched 10 related papers. Consider them for comparative context: